Antares Pharma Appoints Edward Tykot Senior Vice President, Corporate Development
December 10 2019 - 7:00AM
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment
of Edward Tykot to the position of Senior Vice President, Corporate
Development. Mr. Tykot is a seasoned corporate and business
development executive with a proven record of success in both small
and large pharmaceutical companies.
Most recently, Mr. Tykot was Vice President,
Business Development of Nevakar, Inc. Prior to Nevakar, Ed served
as Vice President Business Development and Strategic Planning of
Eagle Pharmaceuticals, Inc. where he was responsible for
identifying and negotiating strategic opportunities for the
organization. Prior to joining Eagle, Mr. Tykot worked at Actavis
plc (formerly Watson Pharmaceuticals) from 1995 until 2014. Ed
served as Executive Director Global Business Development and
Alliance Management from 2010-2014 and Executive Director of
Business Development from 2004 until 2010. He was responsible for
performing strategic assessments of key therapeutic areas for
Actavis’s global brand business. Mr. Tykot identified and screened
opportunities, led cross functional due diligence efforts,
conducted financial modelling and deal valuation, negotiated and
executed deals for both domestic and international markets. Prior
to 2004, Mr. Tykot held various roles of increasing responsibility
at Watson Pharmaceuticals in the marketing and business development
departments. Mr. Tykot started his career at Sandoz. He received
his Master’s in Business Administration from New York University
and received his Bachelor of Science in Biology from Tufts
University.
Robert F. Apple, President and Chief Executive
Officer of the Company, stated, “We are very pleased to have an
experienced executive like Ed join our leadership team at Antares
Pharma. I believe that adding Ed to the Antares team at a time when
we are experiencing tremendous growth in our business will have a
positive impact on our goal to expand our commercial presence and
our pipeline."
About Antares Pharma
Antares Pharma, Inc. is a combination drug
device company focused primarily on the development and
commercialization of self-administered parenteral pharmaceutical
products using advanced drug delivery auto injector technology. The
Company has a portfolio of proprietary and partnered commercial
products with several product candidates in various stages of
development, as well as significant strategic alliances with
industry leading pharmaceutical companies including Teva
Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc.
(AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd.
(Idorsia). Antares Pharma’s proprietary products include XYOSTED®
(testosterone enanthate) injection, OTREXUP® (methotrexate)
injection for subcutaneous use and Sumatriptan Injection USP, which
is distributed by Teva.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are subject to certain risks and
uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences
include, but are not limited to: future successful corporate
development transactions, market acceptance, adequate reimbursement
coverage and commercial success of XYOSTED® and future revenue from
the same; successful development including the timing and results
of the clinical bridging and Phase 3 clinical trial of the drug
device combination product for Selatogrel with Idorsia
Pharmaceuticals and FDA and global regulatory approvals and future
revenue from the same; market acceptance of Teva’s generic
epinephrine auto-injector product and future revenue from the same;
our expectations regarding whether the FDA will pursue withdrawal
of approval for AMAG Pharmaceuticals Inc.’s Makena® subcutaneous
auto injector following the recent FDA advisory committee meeting
and future prescriptions, market acceptance and revenue from
Makena® subcutaneous auto injector; Teva’s ability to successfully
commercialize VIBEX® Sumatriptan Injection USP and the amount of
revenue from the same; continued growth of prescriptions and sales
of OTREXUP®; the timing and results of the Company’s or its
partners’ research projects or clinical trials of product
candidates in development; actions by the FDA or other regulatory
agencies with respect to the Company’s products or product
candidates of its partners; continued growth in product,
development, licensing and royalty revenue; achievement of the 2019
revised revenue guidance; the Company’s ability to meet loan
extension and interest only payment milestones and the ability to
repay the debt obligation to Hercules Capital; the Company’s
ability to obtain financial and other resources for its research,
development, clinical, and commercial activities and other
statements regarding matters that are not historical facts, and
involve predictions. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance, achievements or prospects to be materially
different from any future results, performance, achievements or
prospects expressed in or implied by such forward-looking
statements. In some cases you can identify forward-looking
statements by terminology such as ''may'', ''will'', ''should'',
''would'', ''expect'', ''intend'', ''plan'', ''anticipate'',
''believe'', ''estimate'', ''predict'', ''potential'', ''seem'',
''seek'', ''future'', ''continue'', or ''appear'' or the negative
of these terms or similar expressions, although not all
forward-looking statements contain these identifying words.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K, and in the
Company's other periodic reports and filings with the Securities
and Exchange Commission. The Company cautions investors not to
place undue reliance on the forward-looking statements contained in
this press release. All forward-looking statements are based on
information currently available to the Company on the date hereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this press release, except as required by
law.
Investor Contacts:
Jack HowarthVice President, Corporate
Affairs(609) 359-3016jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Sep 2023 to Sep 2024